Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Rhea-AI Summary

Zealand Pharma (NASDAQ: ZEAL) has disclosed transactions involving its shares conducted by individuals in managerial positions. The announcement highlights ongoing activities surrounding Zealand's innovative peptide-based therapies, including V-Go® and Zegalogue®.

With a pipeline of over 10 drug candidates, including three in late-stage development, the company is positioning itself for potential growth. The company emphasizes its collaborations with major pharmaceutical entities, bolstering its capacity to bring effective treatments to market.

Positive

• Robust pipeline with over 10 drug candidates in clinical development.
• Zegalogue® is the first and only glucagon analogue approved for severe hypoglycemia treatment.
• Collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals expand patient access to Zealand's therapies.

Negative

• None.

Company announcement – No. 26/ 2021

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, DK and Boston, MA, U.S., May 3, 2021 – Zealand Pharma A/S (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached files.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development. Zealand markets V-Go®, abasal-bolus insulin delivery option for people with diabetes and has received approval for Zegalogue® (dasiglucagon), the first and only glucagon analogue for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations
Claudia Styslinger
Argot Partners
investors@zealandpharma.com

Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com

Attachments

• 26_210429_Notification_GKR_rsu
• 27_210429_Notification_JPS_rsu
• 28_210429_Notification_FBB_rsu
• 29_210429_Notification_LGJ_rsu
• 30_210429_Notification_KDrejer_rsu
• 31_210429_Notification_JBerkowitz_rsu
• 32_210429_Notification_BConnaughton_rsu
• 33_210429_Notification_AMunoz_rsu
• 34_210429_Notification_MOwen_rsu
• 35_210429_Notification_LKruimer_rsu
• 36_210429_Notification_MNicklasson_rsu

FAQ

What is the recent stock trading activity for ZEAL?

Zealand Pharma disclosed transactions in its shares by individuals in managerial positions, as part of its regulatory disclosures.

Who are the individuals involved in the recent transactions of ZEAL?

The announcement includes transactions conducted by persons discharging managerial responsibilities or closely associated persons with Zealand Pharma.

How many drug candidates does Zealand Pharma currently have?

Zealand Pharma has over 10 drug candidates in clinical development, with three in late-stage development.

What treatments has Zealand Pharma developed?

Zealand Pharma markets V-Go® and has developed Zegalogue® for treating severe hypoglycemia in diabetes patients.

What collaborations does Zealand Pharma have?

Zealand Pharma has license collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals.